iSTAR Medical announces EUR 40.1 million financing round lead by Gimv to support further development of an innovative glaucoma treatment

GIMV

iSTAR Medical SA, a Wavre-based private medical device company developing novel ophthalmic implants for the treatment of glaucoma, today announces the completion of a EUR 40.1 million Series C financing. The financing was led by Gimv and LSP (Life Sciences Partners), with participation by Earlybird and BNP Paribas Private Equity. Gimv will invest EUR 10 million in total. Existing shareholders including Capricorn Partners, Walloon Region Investment Fund (SRIW) and Belgian Federal Investment Fund (SFPI‐FPIM) also participated. This financing will support iSTAR Medical’s development towards commercialisation of its MINIject device in Europe and US.

iSTAR Medical (https://www.istarmed.com) was founded in 2011 and is a clinical-stage, medical technology company focused on the development of novel ophthalmic implants for patients with glaucoma. Glaucoma is the second leading cause of adult blindness globally affecting more than 92 million people worldwide and driven by an increase in intraocular pressure. Micro-invasive glaucoma surgery (MIGS) is the most promising and fastest-growing therapeutic option in the treatment of glaucoma. iSTAR Medical’s MINIject, an ab-interno MIGS implant, provides a powerful and reliable solution to safely reduce intraocular pressure (IOP) by enhancing aqueous humour outflow from the anterior chamber to the supraciliary space, and has been designed to be a best-in-class MIGS device. Unlike other technologies, MINIject uses the innovative STAR® material, a soft and flexible, medical-grade silicone with a micro-porous, multi-channel geometry.

Bram Vanparys, Partner in Gimv’s Health & Care team, says: “We are looking forward to help building iSTAR Medical to become the leading player in the MIGS field. With the support and expertise of a solid specialized Life Science syndicate, iSTAR Medical now has all the tools to leverage and expand the excellent clinical results of the MINIject. We look forward to support the company in its further development of the MINIject in Europe and the upcoming US pivotal trial.”

This investment marks Gimv’s continued activity in the life sciences sector. With the recent successful exit of Breath Therapeutics and the substantial capital raise in AgroSavfe, the Health & Care platform is committed to further expand the life sciences portfolio.

For more information on this transaction, we refer to the press release of iSTAR Medical in attachment.

Read all press releases

Categories: News

Tags:

Advarra Announces Intent to Acquire Forte, Market-Leading Provider of Clinical Technology Solutions

The move strengthens the site-centric solutions portfolio of the largest global research compliance services organization


COLUMBIA, Md. and MADISON, Wis., September 5, 2019Advarra, the premier provider of institutional review board (IRB), institutional biosafety committee (IBC), and research quality and compliance consulting services, is pleased to announce the intent to acquire Forte, the industry’s leading provider of standards-based clinical research technology solutions for major academic medical centers, cancer centers, and health systems. Forte offers a fully integrated suite of solutions for clinical trial management, clinical data management, and research administration, including OnCore, Forte’s flagship enterprise CTMS.

“Forte is known across the research community as the gold standard for eClinical technology solutions,” said Pat Donnelly, CEO of Advarra. “Their organizational culture and values are the perfect complement to Advarra’s ‘altogether better’ approach to advancing clinical research. We look forward to collaborating with Forte’s customers and team members to continue to enhance their outstanding products and services with additional investment to serve our mutual clients.”

The combined organization supports nearly 100,000 active protocol records with top academic medical centers and health systems. Forte boasts 98 percent cumulative customer retention over 19 years of operation, serving 72 percent of NCI-designated cancer centers and 70 percent of the top 50 NIH-funded research institutions in 2019. The transaction supports continued growth for both businesses, as Advarra offers the greatest institutional reach of any independent IRB, serving well over 3,200 research institutions, health systems, and academic medical centers.

“We’re extremely proud of the highly collaborative customer community we have built over the last 19 years, which has resulted in a site-centric, integrated suite of industry-leading standards-based products and services,” said Shree Kalluri, CEO and Founder of Forte. “Joining Advarra is a great win for the research community and provides an outstanding platform for an interconnected clinical research ecosystem. Together we can transform clinical research and impact patients’ lives through the combination of eClinical technology solutions and research compliance and human subject protection services.”

“After our acquisition of Advarra in July, the Forte transaction represents a significant next step in developing, acquiring, and growing best-in-market solutions for products and services that streamline research, support faster study start-up, and enhance human research protections,” said David Golde, Managing Director of Genstar Capital. “We are excited about the value the combined organization will bring to Advarra and Forte customers.”

Forte is a portfolio company of Primus Capital. Ropes & Gray served as legal counsel to Advarra. Baird served as exclusive financial advisor and Goodwin Proctor LLP served as legal counsel to Forte. The transaction is expected to close later in September.

About Advarra

Advarra, headquartered in Columbia, Md., provides institutional review board (IRB), institutional biosafety committee (IBC) and global research compliance services to clinical trial sponsors, CROs, hospital systems, academic medical centers and investigators. Its robust regulatory expertise and innovative technology ensure the highest standards of research review are met, while putting participants first and meeting complex human research protection oversight requirements. Advarra supports all phases of research across multiple therapeutic areas. For more information, visit advarra.com.

About Forte

Forte provides software and services in the critical areas of clinical trial management, clinical data management, and research administration for cancer centers, academic medical centers, and health systems. With a strong belief in community, collaboration, and standards-based development, Forte also facilitates the Onsemble Community, a customer-exclusive group for peer networking, best practices, and support. Twice a year at the Onsemble Conference, clinical research professionals meet in person and discuss the latest challenges and solutions in clinical research. Forte provides all research professionals complimentary blog articles, eBooks, webinars, and more to support continuous learning on industry topics. For more information, visit forteresearch.com.

About Genstar Capital

Genstar Capital is a leading private equity firm that has been actively investing in high quality companies for over 30 years. Based in San Francisco, Genstar works in partnership with its management teams and its network of strategic advisors to transform its portfolio companies into industry-leading businesses. Genstar currently has approximately $17 billion of assets under management and targets investments focused on targeted segments of the financial services, healthcare, industrial technology, and software industries. For more information on Genstar, please visit www.gencap.com.

About Primus

Capital Primus Capital is a growth-oriented private equity firm focused on investing in leading healthcare, software, and technology-enabled services companies. Primus has invested in over 130 companies, partnering with exceptional management teams to accelerate growth and create shareholder value by applying its industry knowledge, financial resources, and investment experience. For more information about Primus Capital, please visit www.primuscapital.com.

MEDIA INQUIRIES:

Contact: Chris Tofalli
Chris Tofalli Public Relations
914-834-4334

Kinnevik AB (publ) (“Kinnevik”), today announced that it has invested USD 75m in VillageMD.

Kinnevik

Kinnevik AB (publ) (“Kinnevik”), today announced that it has invested USD 75m in VillageMD, a leading US based provider of primary care and a pioneer in the delivery of value-based care. Kinnevik led the USD 100m Series B and will own 10% of VillageMD after the funding round.

VillageMD enables physicians to move towards a primary care-led, risk-bearing clinical model that produces high quality care for patients and strong economic value to physicians. The company was founded in 2013 and has grown to serve more than 2,500 physicians across eight markets in the US. The company cares for approximately 500,000 lives and oversees over USD 3 billion in total medical spend in value-based contracts. VillageMD has a track record in reducing medical spend, improving health and achieving high patient satisfaction.

Kinnevik’s CEO, Georgi Ganev commented: “We are delighted to lead the funding round in VillageMD, a company focused on delivering healthier patients, happier physicians and better outcomes. We have been impressed by the company’s technology, operational and clinical support capabilities, as well as its robust business model. We see VillageMD, our fourth investment in healthcare, as highly complementary to our existing portfolio given its ability to influence a population’s entire healthcare spend. We look forward to supporting VillageMD as the company continues to grow the business.”

Tim Barry, co-founder and CEO of VillageMD, noted: “As we continue to transform and disrupt the healthcare system, we want partners who embrace our mission of changing US health care for the better. We are proud to partner with Kinnevik, who are fully aligned with our ambition to impact more patients and improve the quality of care in our country. We are very excited to have them on board in this next phase in our journey.”

VillageMD will use the funding from the capital raise to expand its primary care footprint in existing and new markets and enhance docOS, its market-leading healthcare operating system. It will also grow its Village Medical brand and scale its Village Medical home care offering.

For further information, visit www.kinnevik.com or contact:

Torun Litzén, Director Investor Relations
Phone +46 (0)70 762 00 50
Email press@kinnevik.com

Kinnevik is an industry focused investment company with an entrepreneurial spirit. Our purpose is to build the digital consumer businesses that provide more and better choice. We do this by working in partnership with talented founders and management teams to create, invest in and lead fast growing businesses in developed and emerging markets. We believe in delivering both shareholder and social value by building well governed companies that contribute positively to society. Kinnevik was founded in 1936 by the Stenbeck, Klingspor and von Horn families. Kinnevik’s shares are listed on Nasdaq Stockholm’s list for large cap companies under the ticker codes KINV A and KINV B.

Categories: News

Tags:

CVC Credit to support Paragon Partners’ acquisition of Pro Optik Group

Pro Optik is Germany’s third largest optician chain with a network of 145 stores, selling 400,000+ spectacles per year

CVC Credit Partners is pleased to announce that it has underwritten a unitranche for Paragon Partners’ management buyout of Pro Optik Group, in partnership with Hannibal Zemariam, Pro Optik’s Managing Director.

Formed in 1987, Pro Optik Group is Germany’s third largest optician chain with a network of 145 stores. The business operates a number of fully owned stores and also a successful partnership model with joint ventures and franchise partners. Its product range includes both branded designer frames as well as private label frames in combination with high-quality lenses, selling around 400,000 spectacles per year. The company also sells contact lenses and has recently added hearing aids to its offering.

Marco Attolini, Managing Partner and Christian Bettinger, Principal of Paragon Partners, commented: “We are delighted to have completed the acquisition of Pro Optik and are very happy to have secured the support of CVC Credit. Their understanding of the market and the vision for the growth of the business ensured that the transaction could be completed in a smooth and timely manner.”

Neale Broadhead, Head of European Private Debt in CVC Credit Partners’ European Private Debt business, added: “Pro Optik is a leading player in a steadily growing market, which is supported by stable underlying socioeconomic factors. It has a strong financial profile, a stable business model and multiple levers for growth. We look forward to supporting both Paragon and Pro Optik in their mutual objective to develop the business organically, through roll-out of the hearing-aid strategy, and potential M&A.”

Categories: News

Tags:

Altas Completes Sale of Capital Vision Services

Altas Partners

Altas Partners today announced that it has completed the sale of Capital Vision Services, LP (“CVS”), a leading provider of management services to vision care practices. CVS provides its affiliated, independent MyEyeDr. optometrists with a complete array of financial, marketing, human resources, and accounting services, along with managed care credentialing and claims processing.

CVS was sold to West Street Capital Partners VII, a fund managed by the Merchant Banking Division of Goldman Sachs. Financial terms of the transaction were not disclosed.

About Altas Partners

Founded in 2012, Altas Partners is an investment firm with a long-term orientation focused on acquiring significant interests in high-quality, market-leading businesses in partnership with outstanding management teams. The firm manages more than $6 billion on behalf of endowments, foundations, public pension funds, and other institutional investors. The firm’s past and present portfolio companies include University of St. Augustine for Health Sciences, Tecta America, Hub International, PADI, Medforth Global Healthcare Education, Capital Vision Services, and NSC Minerals. For more information, please visit https://www.altas.com.

For further information:

Aisha Sánchez
+1 (416) 306-9800
asanchez@altas.com

Categories: News

Tags:

Armilar invests in Tonic App

The medical Tonic App raises 3.5 million euros to conquer Europe

Tonic App, the startup that developed the favourite mobile application of more than 12,000 medical doctors, has raised 3.5 million euros in a round co-led by Vesalius Biocapital Partners (Luxembourg) and Armilar Venture Partners (Portugal), joining Portugal Ventures and TheVentureCity.

With this investment, the company, co-founded and led by Daniela Seixas, will be able to accelerate its European expansion in three of the five largest European healthcare markets – France, Spain and the United Kingdom.

In just two and a half years, the company has developed its mobile platform, obtained the CE marking as medical device, acquired more than 30% of all doctors in Portugal, and entered the Spanish market, where it recently closed its first international deal. Tonic App’s clients include some of the largest healthcare multinational companies such as Medtronic, Novartis, Pfizer and Lilly, and the HR company Randstad. It also has international partnerships for medical events and electronic prescription.

“The digital healthcare market is under significant transformation and that is why this is the right time for a rapid geographic expansion. Medical doctors are increasingly using digital platforms for their work and the other healthcare stakeholders have understood the value of partnering with an independent company that ensures access to an established professional community, ”says Daniela Seixas, CEO of Tonic App and herself a physician. Daniela Seixas adds: “I want to make my colleagues’ day-to-day life easier with the help of technology, to give them more time for what matters the most – their patients. And patients are actually the ultimate vision of Tonic App – more news to follow. ”

Guy Geldhof, managing partner of Vesalius Biocapital III, adds: “Given the fast expansion and fragmentation of knowledge, medical doctors have the natural necessity to communicate with their colleagues and to quickly find the resources they need for their day-to-day work. Tonic App has already demonstrated in Portugal that it can clearly meet the needs of clinicians, having achieved very high penetration rates. It is now making its way into Spain and other strategic markets in Europe. We are convinced that by facilitating the work of physicians, we will be contributing to improving the quality and efficiency of health care and ensure that these professionals have time for the most important – their patients.”

From Armilar Venture Partners, Duarte Mineiro guarantees that “the opportunity to participate in Tonic App brings together a very solid set of attributes against the investment criteria we have defined. We highlight the fact that they have developed a very innovative solution based on a leading academic and professional path of excellence of the main Founder – and it has already shown promising revenue results in such a short time. HealthTech is an area in which we want to further develop our expertise, as we strongly believe in the potential of its value creation within the Portuguese ecosystem. The fact that we can co-invest in a solid and complementary syndicate was another decisive factor in moving forward.”

Rita Marques, CEO of Portugal Ventures (Tonic App’s first investor) states, “We are very proud to see the growth of Tonic App, which will now face the challenge of internationalization – successfully that is all we want. Fully focused on its goals, the team led by Daniela will surely further leverage the technology versus medicine effect, continuing to be a reference in the national Digital Health arena.”

Tonic App is a digital healthcare tool designed to help the medical community diagnose and treat their patients by bringing together all the professional resources they need for their day-to-day work in a single mobile application.

Founded in Porto in 2016 as a spin-off of University of Porto, Tonic App was co-founded by Daniela Seixas, Andrew Barnes, Christophe de Kalbermatten and Dávid Borsós, who were MBA colleagues at IE Business School. On 30 December 2016, Tonic App secured its first venture capital investment with Portugal Ventures. In April 2018, Gonçalo Vilaça joined the executive team as COO. The startup recently completed a growth program with the Spanish- American TheVentureCity in Madrid.

Tonic App has won multiple awards, including the Novartis Techcare Open Innovation Program in 2017, the second prize in the MEDICA Medical App Competition, the world’s largest healthcare trade fair in 2018, and in 2019 SaaStr Europe. Tonic App has been named by Forbes magazine as one of 60 women-led startups that are “revolutionizing technology around the globe”.

For more information about Tonic App:
www.tonicapp.com
Daniela Seixas, CEO – daniela@tonicapp.com | 936099363

About Vesalius Biocapital:

Vesalius Biocapital III is a specialist life sciences venture capital fund and is in line with the predecessor funds Vesalius Biocapital I and Vesalius Biocapital II, which have supported life sciences companies since 2007. Vesalius Biocapital III, launched in April 2017, announced a final close with EUR 120 million in commitments. Vesalius Biocapital I and II raised over EUR 150 million and contributed in the development of over 20 companies. The investment portfolio is well balanced between drug development, medical device & diagnostics and digital health investments and committed to providing capital to science-backed innovation and ambitious entrepreneurs, with a strong focus on exit within five years. The specialist team consists of seasoned life science professionals with experience in the healthcare industry, corporate finance and strategy consulting, supporting companies throughout their growth cycle. The team is based in Europe and explores investment opportunities and valuation potential for the portfolio.

For more information:
www.vesaliusbiocapital-3.com
g.geldhof@vesaliusbiocapital.com

About Armilar Venture Partners:
Armilar Venture Partners is a leader in venture capital fund management in Portugal. An independent venture capital with a 19-year history, a track record of high performance and international presence, Armilar invests in companies in the areas of information and communication technologies (ICT), health technologies (HealthTech) and environment technologies (CleanTech), focusing on strong technology-based early-stage companies. Armilar currently has a total of around € 260 million under management, with five funds typically mobilized as the main investor in seed and early stage transactions of companies in Portugal, Europe and the US. Armilar Venture Partners TechTransfer Fund is supported by InnovFin Equity, with financial support from the European Union under the Horizon 2020 Financial Instruments and the European Fund for Strategic Investments (EFSI), established under the investment plan for Europe. EFSI’s objective is to help support the financing and implementation of productive investments in the European Union and to ensure greater access to financing. The fund is also co-financed by the Capital & Quasi Capital Fund (FC & QC), managed by IFD – Instituição Financeira de Desenvolvimento, S.A.

Baird Capital Portfolio Company Apervtia Merges with Qcentive

Baird Capital

Baird Capital portfolio company Apervita today announced the acquisition of Boston-based Qcentive. The combined Apervita-Qcentive solutions will integrate clinical and financial insights into a single, secure platform to enable healthcare organizations to create value-based contracts that drive greater efficiency and quality of care.

Here the press-release:

Combined company to provide performance measurement, performance improvement and value-based contract administrative solutions to more than 1 in 5 U.S. hospitals and leading insurers

CHICAGO, August 13, 2019 – Apervita, the leading platform for performance-based collaboration in healthcare, today announced the acquisition of Boston-based Qcentive, a leader in value-based contract and alternative payment administration solutions for healthcare organizations. The combined Apervita-Qcentive solutions will integrate clinical and financial insights into a single, secure platform to enable healthcare organizations to create value-based contracts that drive greater efficiency and quality of care.

“Qcentive is the perfect complement to Apervita,” said Paul Magelli, CEO of Apervita. “Apervita has focused on performance measurement and improvement for providers and plans, including the ability to engage providers directly in their workflow. Qcentive’s focus on performance-based contracts between plans and providers and their associated economics is a natural extension.”

“Value-based relationships are critical building blocks to changing the way we buy and sell healthcare,” said Christopher Pilkington, co-founder and CEO of Qcentive. “Linking plans and providers through a trusted secure platform that aligns incentives across quality, efficiency and consumer satisfaction is absolutely essential. The Apervita-Qcentive combination is the first healthcare industry platform with the ingredients to make that happen at scale.”

Qcentive was launched in 2016 by Blue Cross Blue Shield of Massachusetts, a nationally recognized leader for value-based payment innovation. BCBSMA has engaged Apervita and will continue to be a customer of Qcentive technologies.

“Several years ago, we realized we needed a cloud-based analytics solution to make it easier to navigate the complex demands of a new generation of value-based contracts,” said Patrick Gilligan, executive vice president of sales, marketing and product for BCBSMA and CEO of its venture investment subsidiary, Zaffre Investments. “Not finding a solution in the market, we incubated Qcentive with the intent of sharing its innovations with the broader market. The combination of Apervita and Qcentive makes this vision a reality.”

Value-based contracts align financial and clinical quality incentives between healthcare insurance plans and hospitals, physicians, and other clinicians. These contracts establish metrics to measure the quality of care that consumers receive. BCBSMA’s Alternative Quality Contract, one of the largest and longest-running value-based models in the country, has substantially moderated cost growth while producing significant improvements in the quality of patient care, a recent Harvard Medical School study found.

Qcentive was designed to allow other healthcare organizations to create their own value-based models. It provides detailed insights into the quality of clinical care and financial results to both payers and providers on a continuous, year-round basis.

The combined Apervita and Qcentive entity will operate under the Apervita brand with offices in Chicago and Boston.

About Apervita
Apervita, Inc. is the first platform-as-a-service (PaaS) for the healthcare industry that enables providers, payers and their stakeholders to easily connect, build and share critical applications that lower costs, improve consumer and clinician experience, and improve healthcare outcomes. With Apervita, health enterprises can collaborate freely and securely within and outside of their organizations, streamlining, standardizing and auditing quality measures, operational metrics and care pathways. Apervita is used by approximately 1,000 U.S. hospitals.

About Qcentive
Founded in 2016 and based in Boston, Qcentive is the nation’s leading platform for streamlining the administration of value-based contracts and payment relationships in healthcare. The company’s cloud tools support the end-to-end lifecycle of value contract operations, including collaborative modeling and negotiation, rolling financial/clinical performance calculations and reports, actionable insight tied to actual financial rewards, and accurate final settlement/reconciliation.

About Blue Cross Blue Shield of Massachusetts
Blue Cross Blue Shield of Massachusetts is a community-focused, tax-paying, not-for-profit health plan headquartered in Boston. Blue Cross Blue Shield of Massachusetts is committed to the relentless pursuit of quality, affordable healthcare with an unparalleled consumer experience. Consistent with its promise to always put its members first, the company is rated among the nation’s best health plans for member satisfaction and quality.

For further information, contact:
Michelle Schallhorn
Vice President of Marketing
773.320.9788
michelle.schallhorn@apervita.com

Categories: News

Tags:

IK Investment Partners to sell Ellab to EQT

ik-investment-partners

IK Investment Partners (“IK”), a leading Pan-European private equity firm, is pleased to announce  that the IK VIII Fund has reached an agreement to sell Ellab A/S (“Ellab” or “the Company”), a leading global supplier of solutions and services for measuring, recording, monitoring and validating critical parameters of thermal processes to EQT. 

During the past 70 years, Ellab has grown from a small Danish manufacturer of thermometers to a leading global supplier of thermal validation solutions and services. The Company serves both small and large clients within the pharmaceutical, medical and food industries by providing solutions for applications like sterilisation, freeze drying, heat tunnels and pasteurisation, among others. Ellab’s solutions are well known for their industry-leading quality and are used by customers like Pfizer, Astra Zeneca, Mars, Getinge and many hospitals.

During IK’s ownership, Ellab has successfully broadened its product portfolio, executed a M&A strategy and continued to strengthen its organisation. The Company also more than doubled its number of employees over the past three years, creating over 100 new jobs whilst maintaining its strong profitability. Most recently, Ellab extended its offering to monitoring equipment through the acquisition of Hanwell in the UK.

“Thanks to IK, Ellab was able to make significant investments in human capital and strengthen its sales and service organisation, creating value for our customers. They have actively supported our ambitious growth agenda and helped us launch several new products. We now look forward to continuing on our next chapter in the Ellab story,” said Peter Krogh, CEO of Ellab.

“Ellab truly has proven the scalability of its business model, making it the right time to hand over the Company to a new owner. It has been a pleasure working with Peter and all of Ellab’s employees over the past three years and we would like to thank them for all their hard work and dedication,” said Alireza Etemad, Partner at IK Investment Partners and advisor to the IK VIII Fund.

Ellab is the first exit of the IK VIII Fund. Financial terms of the transaction are not disclosed. Completion of the transaction is subject to legal and regulatory approvals.

For further questions, please contact: 

IK Investment Partners
Alireza Etemad, Partner
+46 8 678 95 00

Mikaela Murekian, Director of Communications & ESG
+44 77 87 573 566
mikaela.murekian@ikinvest.com

Ellab A/S
Peter Krogh, CEO
Phone: +45 4452 0500

About IK Investment Partners
IK Investment Partners (“IK”) is a Pan-European private equity firm focused on investments in the Nordics, DACH region, France, and Benelux. Since 1989, IK has raised more than 10 billion of capital and invested in over 125 European companies. IK funds support companies with strong underlying potential, partnering with management teams and investors to create robust, well-positioned businesses with excellent long-term prospects. For more information, visit www.ikinvest.com

About Ellab
Since the late 1940’s Ellab A/S has been a leading manufacturer of complete Thermal Validation Solutions for food, medical, pharmaceutical and other industries where thermal processing involves safety, energy savings, improvement of quality, and optimization. Ellab offers both wireless data loggers and wired thermocouple systems for highly accurate and reliable validation. For more information, visit www.ellab.com

Categories: News

Tags:

Molecular Partners’ strategic partner Allergan announces that EMA has validated the marketing authorisation application for abicipar

Zurich-Schlieren, Switzerland, August 06, 2019. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of drugs known as DARPin® therapies*,  announced on 6 August that the European Medicines Agency (EMA) has validated the marketing authorisation application (MAA) of its strategic partner Allergan for abicipar, a novel DARPin® therapy for the treatment of nAMD. If approved, abicipar is expected to be the first anti-VEGF therapy to sustain vision gains on a true fixed 12-week dosing interval. The validation of the MAA confirms that the submission by the EMA is sufficiently complete to begin the formal review process.

Financial Calendar

August 27, 2019 Publication of Half-year Results 2019 (unaudited)
October 31, 2019 Interim Management Statement Q3 2019
December 12, 2019 R&D Day in New York

http://investors.molecularpartners.com/financial-calendar-and-events/

*DARPin® is a registered trademark owned by Molecular Partners AG

About the DARPin® Difference

DARPin® therapeutics are a new class of protein therapeutics opening an extra dimension of multi-specificity and multi-functionality. DARPin® candidates can engage more than five targets, offering potential benefits over those offered by conventional monoclonal antibodies or other currently available protein therapeutics. The DARPin® technology is a fast and cost-effective drug discovery engine, producing drug candidates with ideal properties for development and very high production yields.

With their low immunogenicity and long half-life in the bloodstream and the eye, DARPin® therapeutics have the potential to advance modern medicine and significantly improve the treatment of serious diseases, including cancer and sight-threatening disorders. Molecular Partners is partnering with Allergan to advance clinical programs in ophthalmology and is advancing a proprietary pipeline of DARPin® drug candidates in oncology and immuno-oncology. The most advanced global product candidate is abicipar, a molecule currently in phase 3, in partnership with Allergan. Several DARPin® molecules for various ophthalmic indications are also in preclinical development. The most advanced DARPin® therapeutic candidate wholly owned by Molecular Partners, MP0250, is in phase 2 clinical development for the treatment of solid and hematological tumors. MP0274, the second-most advanced DARPin® candidate owned by Molecular Partners, binds to Her2 and inhibits downstream signaling, which leads to induction of apoptosis. MP0274 is currently in phase 1. The company’s lead immuno-oncology product candidate MP0310 is a FAP x 4-1BB multi-DARPin® therapeutic candidate designed to locally activate immune cells in the tumor by binding to FAP on tumor stromal cells (localizer) and co-stimulating T cells via 4-1BB (immune modulator). Molecular Partners has closed a collaboration agreement with Amgen for the exclusive clinical development and commercialization of MP0310. MP0310 is expected to enter into the clinic in H2 2019. Molecular Partners is also advancing a growing preclinical and research pipeline in immuno-oncology that features its “I/O toolbox? and additional development programs. DARPin® is a registered trademark owned by Molecular Partners AG.

About Molecular Partners AG

Molecular Partners AG is a clinical-stage biotech company that is developing a new class of therapies known as DARPin® therapeutics. The company continues to attract talented individuals who share the passion to develop breakthrough medicines for serious diseases. Molecular Partners has compounds in various stages of clinical and preclinical development and several more in the research stage, with a current focus on oncology and immuno-oncology. The company establishes research and development partnerships with leading pharmaceutical companies and is backed by established biotech investors.

For more information regarding Molecular Partners AG, go to: www.molecularpartners.com.

For further details, please contact:

Patrick Amstutz, CEO

patrick.amstutz@molecularpartners.com

Tel: +41 44 755 77 00

Lisa Raffensperger, International Media

lisa@tenbridgecommunications.com

Tel: +1 617 903 8783

Thomas Schneckenburger, IR & Media

thomas.schneckenburger@molecularpartners.com

Tel: +41 44 755 5728

Susan A. Noonan, IR USA

susan@sanoonan.com

Tel.: +1 212 966 3650

Categories: News

Tags:

Metalmark Capital Announces Sale of Collagen Matrix

New York, NY– Metalmark Capital (“Metalmark”), a leading private equity firm, announced that it has sold Collagen Matrix, Inc., (“Collagen Matrix”or the “Company”),a global developer and manufacturer of collagen and mineral-based medical devices. Financial terms of the transaction were not disclosed.

Founded in 1997and headquartered in New Jersey, Collagen Matrix is a leading developer and manufacturer of collagen and mineral-based products for tissue repair and regeneration. Leveraging strong product development and internal R&D capabilities, including two state-of-the-art manufacturing facilities, the Company has developed a propriety portfolio of collagen and non-collagen tissue engineering technologies that support the body’s natural ability to heal. Collagen Matrix’s products are suitable across a range of applications, including the growing device sectors of Dental, Neurosurgery, Orthopedics, Spine and Sports Medicine.

“We are proud to have partnered with the strong Collagen Matrix team during a time of considerable success for the Company,” said Howard Hoff en,Chairman and Chief Executive Officer of Metalmark. “Through numerous strategic investments since Metalmark’s investment in late 2014, Collagen Matrix has significantly strengthened its position in the marketplace. We are pleased to have supported Collagen Matrix’s sustained growth and wish the Company continued success as a trusted partner to medical device companies worldwide.

”“I’d like to thank the entire Metalmark team for their incredible collaboration,” said Bart Doedens, CEO of Collagen Matrix.“Under Metalmark’s stewardship, we have scaled our platform by expanding our product suite with innovative solutions spanning multiple clinical focus areas.Collagen Matrix is well positioned to further its proven track record as an innovation leader, delivering high-quality collagen and mineral based products for the diverse needs of our customers.”

Financial and Legal Advisors Robert W. Baird & Co.and Piper Jaffray & Co.acted as financial advisors and Ropes & Gray LLP acted as legal advisor to Collagen Matrix on the transaction.

About Metalmark Capital

Metalmark Capital is a leading private equity firm that seeks to build long-term value through active and collaborative partnerships with business owners, founders, and executives. The firm focuses its investment activity in healthcare, industrials and agribusiness. Metalmark Capital manages funds with $3.7 billion in aggregate capital commitments.

For more information: http://www.metalmarkcapital.com

About Collagen Matrix

Collagen Matrix, Inc., founded in 1997, delivers a full line of the highest-quality collagen and mineral based medical devices that support the body’s natural ability to regenerate. The Company currently manufactures finished medical devices in the areas of Dental, Spine, Orthopedic, Dural Repair and Nerve Repair Surgery. The evolution of the Company’s leadership, proprietary technologies, manufacturing expertise and product portfolio has established a solid foundation for continued growth. Opportunities continue to exist for collaboration through Product Distribution, Product Development and Contract Manufacturing.

More information about Collagen Matrix can be found at www.Collagen Matrix.com.

Media Contacts:

Sard Verbinnen & Co.

Warren Rizzi

Phone: +1 (212) 687-8080

Categories: News

Tags: